BeyondSpring Inc.
BYSIAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Baird | maintain | Outperform | May 2, 2023 |
| Jefferies | downgrade | Buy →Hold | Dec 2, 2021 |
| B of A Securities | downgrade | Buy →Underperform | Dec 2, 2021 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Dec 1, 2021 |
| HC Wainwright & Co. | maintain | Buy | Sep 20, 2021 |
| Baird | maintain | Outperform | Sep 9, 2021 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Aug 4, 2021 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Apr 5, 2021 |
| B of A Securities | maintain | Buy | Jan 11, 2021 |
| Evercore ISI Group | maintain | Outperform | Dec 29, 2020 |
| HC Wainwright & Co. | maintain | Buy | Jun 15, 2020 |
| HC Wainwright & Co. | maintain | Buy | Mar 30, 2020 |
| Jefferies | maintain | Buy | Feb 7, 2020 |
| Nomura Instinet | maintain | Buy | Jan 10, 2020 |
| William Blair | maintain | Outperform | Dec 3, 2019 |
| Maxim Group | maintain | Buy | Jun 22, 2018 |
| Rodman & Renshaw | maintain | Buy | Apr 4, 2017 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.54| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.02 | $-0.54 | — | $8.8M |
| May 13, 2026 | $-0.05 | $-0.54 | — | $8.8M |
| Mar 25, 2026 | $-0.05 | $-0.54 | — | — |
| Nov 12, 2025 | $-0.05 | — | — | — |
| Aug 13, 2025 | $-0.04 | — | — | — |
| May 12, 2025 | $-0.06 | — | — | — |
| Mar 27, 2025 | $0.08 | — | -$1.4M | — |
| Aug 9, 2024 | $-0.09 | — | $500.0K | — |
News
BeyondSpring Inc. (BYSI) Shareholder/Analyst Call Prepared Remarks Transcript
BeyondSpring (NASDAQ: BYSI) said the U.S. Food and Drug Administration has granted Fast Track designation to plinabulin in combination with docetaxel for patients with second- or third-line non-squamous non-small cell lung cancer (NSCLC) who have progressed after immune checkpoint inhibitor treatment and platinum-based chemotherapy and do not have actionable genomic alterations. The company also disclosed a
BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript
FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing innovative therapies for the treatment of cancer and other diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to Plinabulin and docetaxel for the treatment of patients with advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”) without actionable genomic alterat…
ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy